AzurRx BioPharma Inc (NASDAQ:AZRX) Given Average Rating of “Buy” by Brokerages

Shares of AzurRx BioPharma Inc (NASDAQ:AZRX) have earned an average recommendation of “Buy” from the seven ratings firms that are covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $7.42.

Several research analysts have commented on the stock. Maxim Group reissued a “buy” rating and set a $5.00 price objective on shares of AzurRx BioPharma in a report on Wednesday, April 24th. ValuEngine raised shares of AzurRx BioPharma from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. National Securities assumed coverage on shares of AzurRx BioPharma in a report on Tuesday, June 11th. They set a “buy” rating and a $9.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of AzurRx BioPharma in a research report on Wednesday.

Shares of AZRX traded down $0.03 during midday trading on Thursday, hitting $0.96. 63,500 shares of the company traded hands, compared to its average volume of 137,231. The firm has a 50 day simple moving average of $1.19. AzurRx BioPharma has a 52 week low of $0.86 and a 52 week high of $3.75. The stock has a market cap of $25.58 million, a PE ratio of -1.09 and a beta of 2.21.

AzurRx BioPharma (NASDAQ:AZRX) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.08). Equities research analysts anticipate that AzurRx BioPharma will post -0.76 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in AZRX. Vanguard Group Inc. boosted its holdings in AzurRx BioPharma by 255.0% in the second quarter. Vanguard Group Inc. now owns 260,306 shares of the company’s stock worth $443,000 after purchasing an additional 186,985 shares during the period. BlackRock Inc. boosted its holdings in AzurRx BioPharma by 57.6% in the second quarter. BlackRock Inc. now owns 42,313 shares of the company’s stock worth $72,000 after purchasing an additional 15,463 shares during the period. JPMorgan Chase & Co. acquired a new position in AzurRx BioPharma in the second quarter worth $57,000. Regentatlantic Capital LLC acquired a new position in AzurRx BioPharma in the first quarter worth $48,000. Finally, Waldron Private Wealth LLC acquired a new position in AzurRx BioPharma in the first quarter worth $169,000. Hedge funds and other institutional investors own 10.59% of the company’s stock.

AzurRx BioPharma Company Profile

AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.

Further Reading: 52-Week High/Low Prices For Stock Selection

Analyst Recommendations for AzurRx BioPharma (NASDAQ:AZRX)

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit